Numab Entered into a Development and License Agreement with Ono to Develop Immuno-Oncology Therapies for the Treatment of Cancer
Shots:
- Numab to receive ~$279.13M in research funding, up front and milestone along with royalties on future sales. Under the terms of the license agreement, Ono gets the intellectual property rights and exclusive global development and commercialization rights for a multispecific antibody targeting a novel immuno-oncology target
- The collaboration will combine Numab’s multispecific antibody platform and Ono’s deep immuno-oncology expertise to advance the immuno-oncology pipeline for cancer patients
- In Mar 2020, Numab has expanded its collaboration with Ono to discover and develop a multispecific antibody drug candidate for the treatment of multiple cancers
Ref: Businesswire | Image: Businesswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.